Related Experiment Video

Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins and other agents for vascular inflammation

Christopher D Owens1

  • 1University of California San Francisco Medical Center, San Francisco, CA 94148, USA. christopher.owens@ucsfmedctr.org

Journal of Vascular Surgery
|September 29, 2012
PubMed

Insights

Atherosclerosis is an inflammatory disease. Novel anti-inflammatory drugs, distinct from statins, are being tested to reduce cardiovascular risk by targeting inflammation directly, independent of cholesterol levels.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Pharmacology

Background:

  • Atherosclerosis and its clinical outcomes are increasingly understood as inflammatory conditions.
  • Circulating inflammatory biomarkers, particularly high-sensitivity C-reactive protein, independently predict cardiovascular risk.
  • Statins reduce cardiovascular risk and inflammatory markers, but their effects are confounded by cholesterol reduction.

Purpose of the Study:

  • To evaluate the hypothesis that targeted anti-inflammatory therapies can improve cardiovascular outcomes.
  • To investigate novel anti-inflammatory agents that reduce inflammatory markers without impacting lipids, glucose, or blood pressure.

Main Methods:

  • Review of clinical trials investigating statins as anti-inflammatory agents.
  • Analysis of ongoing trials for novel anti-inflammatory drugs.
  • Examination of inflammatory biomarkers in cardiovascular risk prediction.

Main Results:

  • High-sensitivity C-reactive protein is a robust predictor of cardiovascular risk.
  • Statin trials provide a basis for testing specific anti-inflammatory agents.
  • Novel agents aim to reduce inflammation without altering metabolic parameters.

Conclusions:

  • Targeting inflammation is a promising strategy for cardiovascular risk reduction.
  • Future trials with specific anti-inflammatory drugs will clarify the role of inflammation in vascular disease.
  • Understanding the inflammation-vascular risk relationship is crucial for developing new therapies.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...